measureName,measureId,submissionMethod,measureType,standardDeviation,averagePerformanceRate,isToppedOut,isToppedOutByProgram,percentile1,percentile10,percentile20,percentile30,percentile40,percentile50,percentile60,percentile70,percentile80,percentile90,percentile99,isHighPriority,isInverse,metricType
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001,MIPS CQM,Intermediate Outcome,21.914788843548816,23.12,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,Y,singlePerformanceRate
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001,Medicare Part B Claims,Intermediate Outcome,6.389577272019824,1.68,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,Y,singlePerformanceRate
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001,eCQM,Intermediate Outcome,29.02317313548391,40.91,No,No,0.44,12.5,17.18,20.86,24.85,29.525,36.72,49.53,71.68,93.98,99.49,Y,Y,singlePerformanceRate
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001SSP,MIPS CQM,Intermediate Outcome,17.77524536606628,25.78,No,No,3.87,7.03,10.14,14.33,18.93,22.27,25.93,29.76,38.28,49.19,80.94,Y,Y,singlePerformanceRate
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),005,MIPS CQM,Process,7.137296143049173,97.23,Yes,Yes,73.4,87.69,96.62,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),005,eCQM,Process,10.32167290086207,81.04,No,No,50.0,67.35,74.19,77.34,79.77,81.74,83.82,86.19,89.54,93.33,100.0,N,N,singlePerformanceRate
Coronary Artery Disease (CAD): Antiplatelet Therapy,006,MIPS CQM,Process,14.729578245813201,91.60,Yes,No,38.16,70.14,80.57,92.16,99.38,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),007,MIPS CQM,Process,6.100647019485563,97.61,Yes,No,75.0,90.82,98.15,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),007,eCQM,Process,9.34578730455142,87.44,No,No,55.56,78.46,82.7,85.48,87.5,89.25,90.49,91.91,93.55,95.97,100.0,N,N,singlePerformanceRate
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),008,MIPS CQM,Process,5.6286018490838545,98.50,Yes,Yes,69.05,95.79,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),008,eCQM,Process,7.9821393851367715,91.56,No,No,57.14,83.33,87.93,90.32,92.19,93.645,94.74,95.65,96.67,98.15,100.0,N,N,singlePerformanceRate
Anti-Depressant Medication Management,009,eCQM,Process,17.130463645297738,61.23,No,No,18.13,40.94,50.43,55.1,57.55,59.86,62.45,65.38,72.12,86.67,100.0,N,N,multiPerformanceRate
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,012,eCQM,Process,30.192589390370166,76.19,No,No,0.84,20.37,51.72,73.41,83.98,91.3,94.93,97.23,99.09,100.0,100.0,N,N,singlePerformanceRate
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,MIPS CQM,Process,14.469847177786432,96.03,Yes,Yes,14.75,94.38,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,eCQM,Process,20.02913930347259,86.65,No,No,6.56,60.47,81.27,88.52,92.24,94.3,96.23,97.75,99.01,100.0,100.0,Y,N,singlePerformanceRate
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,024,MIPS CQM,Process,29.369728376241167,85.30,Yes,Yes,0.84,17.82,83.78,93.49,97.73,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,024,Medicare Part B Claims,Process,0.0,100.00,Yes,No,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,MIPS CQM,Process,30.97715439587936,59.10,No,No,0.31,6.37,28.87,45.5,55.71,63.96,72.03,80.65,88.955,99.0,100.0,N,N,singlePerformanceRate
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,Medicare Part B Claims,Process,27.467472594172328,76.84,No,No,0.68,32.35,57.28,67.44,79.01,87.255,94.63,98.68,100.0,100.0,100.0,N,N,singlePerformanceRate
Advance Care Plan,047,MIPS CQM,Process,28.82527420641193,82.98,Yes,No,0.33,30.94,68.45,86.9,95.62,99.13,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Advance Care Plan,047,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,048,MIPS CQM,Process,21.92505204234516,90.83,Yes,Yes,1.26,64.66,92.02,98.65,99.96,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,050,MIPS CQM,Process,16.502589038949225,93.17,Yes,No,1.51,81.97,89.58,96.57,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation for Long-Acting Inhaled Bronchodilator Therapy,052,MIPS CQM,Process,23.999162252890823,85.98,Yes,Yes,0.42,45.05,73.64,90.38,95.74,98.76,100.0,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Appropriate Treatment for Upper Respiratory Infection (URI),065,MIPS CQM,Process,9.97005496712184,96.20,Yes,No,38.75,91.8,95.71,97.68,98.89,99.51,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Treatment for Upper Respiratory Infection (URI),065,eCQM,Process,14.253378610128024,88.61,No,No,33.33,70.92,82.26,87.5,90.71,93.165,95.35,97.16,99.02,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Testing for Pharyngitis,066,MIPS CQM,Process,10.196871636257942,96.54,Yes,Yes,27.08,89.13,95.45,98.87,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Testing for Pharyngitis,066,eCQM,Process,26.636064232293073,71.29,No,No,2.0,21.04,53.25,67.42,75.63,81.03,86.04,89.42,92.09,94.95,98.96,Y,N,singlePerformanceRate
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis,116,MIPS CQM,Process,15.920954970215073,91.71,Yes,No,21.05,80.73,90.77,93.83,95.7,97.395,98.27,99.53,100.0,100.0,100.0,Y,N,singlePerformanceRate
Diabetes: Eye Exam,117,MIPS CQM,Process,20.99460291582041,91.80,Yes,Yes,1.8,71.07,93.2,99.38,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Diabetes: Eye Exam,117,eCQM,Process,39.56689493960224,62.05,No,No,0.45,5.88,15.38,26.78,43.01,80.365,98.93,99.63,100.0,100.0,100.0,N,N,singlePerformanceRate
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),118,MIPS CQM,Process,11.754727408226778,91.08,Yes,No,47.46,76.485,82.65,86.63,90.78,96.61,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,MIPS CQM,Process,30.9578988988768,80.25,Yes,Yes,0.32,21.28,57.4,79.84,94.06,99.46,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,MIPS CQM,Process,25.898609224633176,86.80,Yes,Yes,0.54,42.0,80.83,94.62,99.28,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,MIPS CQM,Process,38.31578498379919,58.11,No,No,0.17,7.38,17.24,20.56,49.56,70.54,86.21,93.48,96.69,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,eCQM,Process,28.16325816241048,71.71,No,No,4.5,31.26,38.65,61.6,77.91,85.71,90.17,91.5,94.76,96.69,99.49,N,N,singlePerformanceRate
Documentation of Current Medications in the Medical Record,130,MIPS CQM,Process,21.338960570284076,92.26,Yes,Yes,3.65,78.38,96.34,99.49,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Documentation of Current Medications in the Medical Record,130,eCQM,Process,20.959550764749075,87.08,Yes,Yes,2.94,60.96,80.45,88.9,93.33,95.98,97.76,98.87,99.65,99.96,100.0,Y,N,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,MIPS CQM,Process,27.59229023754353,85.58,Yes,Yes,0.07,40.34,76.3,94.01,98.97,99.82,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Medicare Part B Claims,Process,14.208692428205136,95.64,Yes,Yes,24.03,87.86,99.55,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,eCQM,Process,32.20029952016803,45.55,No,No,0.07,2.7,11.42,21.65,31.79,42.685,53.935,67.48,80.72,93.44,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134SSP,MIPS CQM,Process,22.04773457518013,62.87,No,No,11.44,32.51,45.67,54.49,59.27,65.56,70.55,76.11,82.17,92.34,99.78,N,N,singlePerformanceRate
Melanoma: Continuity of Care - Recall System,137,MIPS CQM,Structure,10.834640966551495,97.56,No,No,34.48,98.4,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 20% OR Documentation of a Plan of Care.,141,MIPS CQM,Outcome,9.670551940047869,98.17,Yes,No,34.95,98.45,99.4,99.69,99.87,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 20% OR Documentation of a Plan of Care.,141,Medicare Part B Claims,Outcome,19.402245099577947,93.64,No,No,12.12,81.13,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Oncology: Medical and Radiation - Pain Intensity Quantified,143,MIPS CQM,Process,17.04746339267189,92.71,Yes,Yes,17.5,75.09,93.26,97.76,99.65,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Oncology: Medical and Radiation - Pain Intensity Quantified,143,eCQM,Process,32.44903137844283,77.99,Yes,Yes,1.27,12.0,52.88,80.59,91.73,96.305,97.97,98.9,99.72,100.0,100.0,Y,N,singlePerformanceRate
Oncology: Medical and Radiation - Plan of Care for Pain,144,MIPS CQM,Process,24.193456313745244,83.56,Yes,No,6.06,48.65,67.55,80.56,89.71,96.705,99.51,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy,145,MIPS CQM,Process,22.217177563954067,91.31,Yes,No,1.83,68.31,95.04,99.28,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy,145,Medicare Part B Claims,Process,27.159563365989214,86.28,Yes,No,1.44,35.0,80.3,95.345,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Falls: Plan of Care,155,MIPS CQM,Process,14.148728639300758,96.30,Yes,Yes,16.19,95.38,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Falls: Plan of Care,155,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy,176,MIPS CQM,Process,29.980320493689003,80.36,Yes,Yes,4.0,25.0,52.94,79.53,94.44,99.17,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,MIPS CQM,Process,14.275237381955268,93.41,Yes,Yes,24.33,81.585,90.65,96.34,98.52,99.62,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Rheumatoid Arthritis (RA): Functional Status Assessment,178,MIPS CQM,Process,19.66823466711616,91.32,Yes,Yes,0.11,64.73,90.91,97.53,99.4,99.89,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,MIPS CQM,Process,14.608298422282925,92.89,Yes,Yes,13.67,78.44,90.77,92.96,96.64,99.8,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Elder Maltreatment Screen and Follow-Up Plan,181,MIPS CQM,Process,18.690452044472494,94.05,Yes,Yes,0.71,79.4,99.3,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Elder Maltreatment Screen and Follow-Up Plan,181,Medicare Part B Claims,Process,18.0566387097208,95.30,Yes,Yes,0.71,98.51,99.83,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Outcome Assessment,182,MIPS CQM,Process,8.477057802885335,98.62,Yes,Yes,57.69,99.59,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use,185,MIPS CQM,Process,8.414502554926884,97.41,Yes,Yes,68.3,93.33,97.73,99.79,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,MIPS CQM,Process,9.139281712025145,97.61,Yes,Yes,51.72,95.45,98.9,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,MIPS CQM,Outcome,8.384839149144165,97.81,Yes,No,68.18,96.17,99.18,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,eCQM,Outcome,10.072927267356281,95.45,No,No,41.31,92.02,94.99,96.415,97.405,98.07,98.68,99.135,99.705,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Knee Impairments,217,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.34906879679199,78.83,No,No,6.67,44.07,61.9,67.66,76.74,83.5,93.94,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Hip Impairments,218,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.322559817752367,78.38,No,No,19.35,47.37,58.33,67.5,75.0,81.6,93.75,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
"Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments",219,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.497458477759942,78.79,No,No,11.76,45.37,59.18,68.64,78.26,83.33,92.31,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Low Back Impairments,220,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.40874609197321,78.90,No,No,15.79,41.18,60.0,69.57,78.38,85.11,93.75,97.9,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Shoulder Impairments,221,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.376878455792813,78.26,No,No,18.18,42.7,59.84,70.83,77.17,84.53,91.3,96.72,100.0,100.0,100.0,Y,N,singlePerformanceRate
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),20.63223709927701,80.76,No,No,30.0,52.27,63.64,66.67,73.42,86.125,98.39,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,MIPS CQM,Process,25.709760122745546,85.77,Yes,No,4.17,41.67,75.0,90.77,98.65,100.0,100.0,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Medicare Part B Claims,Process,17.259164274982915,93.70,Yes,Yes,8.51,80.0,95.65,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,eCQM,Process,31.180799532273642,66.95,No,No,4.17,19.23,33.33,46.58,61.57,75.97,87.41,94.74,98.82,100.0,100.0,N,N,multiPerformanceRate
Controlling High Blood Pressure,236,MIPS CQM,Intermediate Outcome,20.175867050495118,68.71,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,N,singlePerformanceRate
Controlling High Blood Pressure,236,Medicare Part B Claims,Intermediate Outcome,17.227100971495872,79.68,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,N,singlePerformanceRate
Controlling High Blood Pressure,236,eCQM,Intermediate Outcome,17.24471289915838,66.06,No,No,4.76,45.28,55.56,61.54,65.61,68.98,72.0,75.0,78.7,84.04,98.18,Y,N,singlePerformanceRate
Controlling High Blood Pressure,236SSP,MIPS CQM,Intermediate Outcome,15.193681731858513,67.87,No,No,13.68,44.87,62.33,68.17,70.15,72.54,74.09,74.7,76.42,82.81,90.53,Y,N,singlePerformanceRate
Use of High-Risk Medications in Older Adults,238,MIPS CQM,Process,6.845471889612883,0.70,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.02,9.62,Y,Y,multiPerformanceRate
Use of High-Risk Medications in Older Adults,238,eCQM,Process,7.540113436393829,4.79,Yes,Yes,0.0,0.0,0.0,0.0,0.14,0.66,2.02,5.23,10.16,15.85,30.71,Y,Y,multiPerformanceRate
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents,239,eCQM,Process,18.965652952159072,39.37,No,No,2.94,22.69,26.91,29.53,31.79,33.33,36.51,42.3,53.545,68.395,95.38,N,N,multiPerformanceRate
Childhood Immunization Status,240,eCQM,Process,14.110425274249176,24.80,No,No,1.23,8.0,12.93,16.39,19.51,23.065,27.02,30.67,35.14,43.48,67.49,N,N,singlePerformanceRate
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,MIPS CQM,Process,31.48424251252206,72.12,No,No,2.86,34.78,38.28,40.91,69.68,89.145,97.09,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Barrett's Esophagus,249,MIPS CQM,Process,6.605617056113947,99.52,Yes,Yes,98.53,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Barrett's Esophagus,249,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Radical Prostatectomy Pathology Reporting,250,MIPS CQM,Process,0.7212934077569146,99.90,Yes,Yes,97.5,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Radical Prostatectomy Pathology Reporting,250,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,MIPS CQM,Process,7.843990471951387,96.65,Yes,Yes,58.06,91.3,95.24,97.14,98.705,99.72,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,MIPS CQM,Process,29.113300503496625,85.24,Yes,No,4.35,27.74,72.67,97.725,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,MIPS CQM,Process,36.81022972596779,71.11,Yes,No,0.44,6.82,27.68,55.69,77.38,95.6,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Sleep Apnea: Assessment of Adherence to Obstructive Sleep Apnea (OSA) Therapy.,279,MIPS CQM,Process,8.190730163294525,98.17,Yes,Yes,45.97,99.63,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Dementia: Cognitive Assessment,281,eCQM,Process,30.75845902267008,40.97,No,No,0.38,3.23,8.04,15.38,25.61,38.95,50.0,58.37,71.35,86.89,100.0,N,N,singlePerformanceRate
Dementia: Functional Status Assessment,282,MIPS CQM,Process,15.097479355935851,96.36,Yes,Yes,4.09,98.59,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia,286,MIPS CQM,Process,15.19000017226757,96.57,Yes,Yes,3.7,97.21,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Dementia: Education and Support of Caregivers for Patients with Dementia,288,MIPS CQM,Process,14.090237067802148,96.98,Yes,Yes,12.86,99.07,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Assessment of Mood Disorders and Psychosis for Patients with Parkinson's Disease,290,MIPS CQM,Process,12.900717700245329,96.22,Yes,Yes,1.4,85.71,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Assessment of Cognitive Impairment or Dysfunction for Patients with Parkinson's Disease,291,MIPS CQM,Process,14.76064081272243,94.04,Yes,Yes,23.06,78.68,92.31,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Rehabilitative Therapy Referral for Patients with Parkinson's Disease,293,MIPS CQM,Process,16.799256060326055,95.08,Yes,No,9.09,91.3,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Initiation and Engagement of Substance Use Disorder Treatment,305,eCQM,Process,8.08516602070972,7.86,No,No,0.4,1.79,2.85,3.82,4.64,5.56,6.63,8.0,10.5,16.2,41.67,Y,N,multiPerformanceRate
Cervical Cancer Screening,309,eCQM,Process,24.535931180575567,42.47,No,No,0.27,5.56,19.05,29.41,36.7,43.295,49.53,55.85,63.64,73.55,99.7,N,N,singlePerformanceRate
Chlamydia Screening for Women,310,eCQM,Process,19.224783780731105,19.72,No,No,0.27,1.55,2.79,4.35,7.47,13.09,20.0,28.66,35.54,47.81,74.24,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,MIPS CQM,Process,34.198384811466354,73.53,Yes,No,0.13,18.855,32.485,54.275,82.65,97.655,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Medicare Part B Claims,Process,28.249854525159027,87.15,Yes,Yes,0.27,34.76,89.99,98.33,99.68,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,eCQM,Process,19.52590801287151,28.13,No,No,0.05,5.05,15.11,19.845,23.195,26.24,29.12,32.26,36.555,45.84,100.0,N,N,singlePerformanceRate
Falls: Screening for Future Fall Risk,318,eCQM,Process,34.34438977019419,67.34,No,No,0.15,7.93,29.04,50.47,67.97,81.565,90.86,96.67,99.05,99.86,100.0,Y,N,singlePerformanceRate
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,MIPS CQM,Process,17.6908065296427,93.54,Yes,Yes,5.73,88.74,95.3,97.73,99.15,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients,322,MIPS CQM,Efficiency,8.237004976535928,0.80,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,3.49,Y,Y,singlePerformanceRate
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,MIPS CQM,Process,15.121959689292078,92.45,Yes,Yes,30.0,71.43,86.44,95.77,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse),331,MIPS CQM,Process,29.737402379749756,24.51,No,No,0.0,0.0,0.0,0.0,3.45,8.33,18.75,38.6,59.17,74.35,91.67,Y,Y,singlePerformanceRate
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,MIPS CQM,Process,14.26429122362052,92.42,Yes,No,31.69,75.73,88.89,92.98,96.29,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
HIV Viral Suppression,338,MIPS CQM,Outcome,5.813803876943922,95.49,Yes,No,76.6,89.19,90.93,93.16,95.12,98.72,99.48,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
HIV Medical Visit Frequency,340,MIPS CQM,Process,18.627582005285504,85.93,Yes,No,34.25,65.38,71.51,75.45,87.3,95.83,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Total Knee or Hip Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,MIPS CQM,Process,32.83227225578174,82.49,Yes,No,0.05,16.36,50.0,99.58,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Total Knee or Hip Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,MIPS CQM,Process,19.9597407936392,92.60,Yes,No,2.5,67.96,96.98,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Anastomotic Leak Intervention,354,MIPS CQM,Outcome,2.3020831204690215,0.96,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.62,4.63,8.33,Y,Y,singlePerformanceRate
Unplanned Reoperation within the 30 Day Postoperative Period,355,MIPS CQM,Outcome,2.742999926533741,0.35,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.4,5.0,Y,Y,singlePerformanceRate
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,MIPS CQM,Outcome,1.602228008491603,0.79,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.45,3.03,6.73,Y,Y,singlePerformanceRate
Surgical Site Infection (SSI),357,MIPS CQM,Outcome,0.7155847601816652,0.18,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.51,4.55,Y,Y,singlePerformanceRate
Patient-Centered Surgical Risk Assessment and Communication,358,MIPS CQM,Process,26.746147098742995,88.96,Yes,Yes,0.85,45.71,95.04,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,MIPS CQM,Process,29.65148546425096,87.98,Yes,Yes,0.01,28.58,95.83,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,MIPS CQM,Process,19.114571363747054,90.84,Yes,Yes,15.77,64.56,83.09,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Follow-Up Care for Children Prescribed ADHD Medication (ADD),366,eCQM,Process,18.20720259957118,44.14,No,No,11.89,23.91,29.74,33.33,37.195,40.68,46.605,51.35,56.645,65.62,100.0,N,N,multiPerformanceRate
Depression Remission at Twelve Months,370,eCQM,Outcome,13.18240551755288,13.93,No,No,0.83,2.36,4.46,6.06,7.86,10.0,12.5,15.7,20.0,28.69,66.67,Y,N,multiPerformanceRate
Closing the Referral Loop: Receipt of Specialist Report,374,MIPS CQM,Process,23.652423265493347,89.54,Yes,Yes,1.54,56.72,90.0,97.37,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Closing the Referral Loop: Receipt of Specialist Report,374,eCQM,Process,30.98792073688284,46.43,No,No,0.57,5.77,15.69,24.96,33.79,42.86,52.175,62.5,79.54,95.76,100.0,Y,N,singlePerformanceRate
Functional Status Assessment for Total Hip Replacement,376,eCQM,Process,21.053534189485053,27.35,No,No,0.73,3.89,6.27,9.38,16.0,27.43,31.82,38.1,46.72,55.81,85.71,Y,N,singlePerformanceRate
Functional Status Assessments for Heart Failure,377,eCQM,Process,5.16861137305186,3.95,No,No,0.04,0.17,0.285,0.7,0.83,1.09,2.71,4.465,6.655,12.305,22.59,Y,N,singlePerformanceRate
Children Who Have Dental Decay or Cavities,378,eCQM,Outcome,24.88428855716087,26.90,No,No,0.0,3.34,7.45,8.47,12.32,16.3,25.93,43.48,47.94,59.86,97.92,Y,Y,singlePerformanceRate
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,eCQM,Process,11.40092781428139,20.86,No,No,3.17,5.05,11.11,13.91,16.05,19.17,23.39,25.53,32.85,36.4,42.22,N,N,singlePerformanceRate
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,eCQM,Process,32.027393879696746,41.11,No,No,0.4,1.99,5.05,17.78,26.97,37.97,45.33,58.18,72.2,92.65,100.0,Y,N,singlePerformanceRate
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,MIPS CQM,Intermediate Outcome,32.55953327456987,84.19,No,No,1.15,3.66,75.79,97.66,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,MIPS CQM,Outcome,6.57751949005089,94.65,Yes,Yes,71.43,87.1,91.95,93.33,94.67,96.67,97.14,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,MIPS CQM,Outcome,8.569196295260557,79.26,No,No,59.09,68.18,71.88,75.0,77.39,80.0,81.82,83.67,85.755,89.8,100.0,Y,N,singlePerformanceRate
Immunizations for Adolescents,394,MIPS CQM,Process,25.563697318289346,47.42,No,No,1.75,18.42,24.32,30.63,36.65,43.33,51.72,60.0,71.43,85.19,100.0,N,N,multiPerformanceRate
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,MIPS CQM,Process,2.180541736356661,99.62,Yes,Yes,87.14,99.925,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Medicare Part B Claims,Process,13.225895631067955,95.96,Yes,Yes,30.0,92.11,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Lung Cancer Reporting (Resection Specimens),396,MIPS CQM,Process,0.867210128744686,99.85,Yes,Yes,95.24,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Melanoma Reporting,397,MIPS CQM,Process,13.478862305370125,97.14,Yes,Yes,23.63,98.85,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Melanoma Reporting,397,Medicare Part B Claims,Process,1.3835429485294388,99.53,Yes,Yes,94.44,97.94,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Optimal Asthma Control,398,MIPS CQM,Outcome,25.35499505749805,80.16,No,No,14.81,33.33,59.42,73.42,82.96,95.38,98.54,100.0,100.0,100.0,100.0,Y,N,multiPerformanceRate
One-Time Screening for Hepatitis C Virus (HCV) and Treatment Initiation,400,MIPS CQM,Process,24.866205374164853,12.24,No,No,0.08,0.35,1.01,1.97,2.66,3.335,4.66,7.05,9.49,33.23,100.0,N,N,multiPerformanceRate
Anesthesiology Smoking Abstinence,404,MIPS CQM,Intermediate Outcome,20.056504568737253,79.89,No,No,12.6,52.94,65.84,75.45,80.37,84.3,87.93,93.13,98.35,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,MIPS CQM,Process,33.88209725565544,79.03,Yes,Yes,0.49,10.34,46.15,78.17,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Medicare Part B Claims,Process,33.68421308881105,61.15,No,No,0.6,10.555,21.7,36.665,59.215,72.62,81.255,87.135,92.5,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,MIPS CQM,Process,14.73993687912878,5.44,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,5.17,17.95,90.48,Y,Y,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Medicare Part B Claims,Process,18.342965428356518,9.16,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,5.71,12.39,25.0,80.0,Y,Y,singlePerformanceRate
Psoriasis: Clinical Response to Systemic Medications,410,MIPS CQM,Outcome,21.304774956545735,88.39,No,No,6.67,59.26,80.25,90.91,97.37,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,MIPS CQM,Efficiency,6.516523541459053,97.14,Yes,Yes,63.39,93.9,96.69,97.76,98.5,99.44,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,MIPS CQM,Efficiency,11.251575834070241,4.57,No,No,0.0,0.0,0.0,0.0,0.0,0.0,2.0,3.45,4.35,14.04,61.9,Y,Y,singlePerformanceRate
Osteoporosis Management in Women Who Had a Fracture,418,MIPS CQM,Process,21.67012468834324,23.18,No,No,1.56,6.23,9.23,11.89,14.01,16.36,19.28,23.08,30.34,47.73,100.0,N,N,singlePerformanceRate
Overuse of Imaging for the Evaluation of Primary Headache,419,MIPS CQM,Process,1.6292603830292278,0.17,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,5.77,Y,Y,singlePerformanceRate
Perioperative Temperature Management,424,MIPS CQM,Outcome,1.8163597831100815,99.44,Yes,Yes,93.35,98.375,99.615,99.87,99.995,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,MIPS CQM,Process,1.5783773731536117,99.34,Yes,Yes,90.2,98.08,99.27,99.65,99.91,99.99,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,MIPS CQM,Process,36.31731892741423,69.11,No,No,1.06,8.33,22.86,50.0,71.43,88.89,99.3,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,MIPS CQM,Process,11.034901016391816,97.64,Yes,Yes,9.72,96.91,99.68,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Medicare Part B Claims,Process,23.713160750189378,90.74,Yes,Yes,0.4,66.59,95.065,98.62,99.6,99.82,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,MIPS CQM,Process,21.068358868120093,75.60,No,No,15.88,42.85,58.74,68.81,73.655,78.03,83.525,89.27,99.775,100.0,100.0,N,N,singlePerformanceRate
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,eCQM,Process,11.911612010126111,78.25,No,No,24.47,67.86,73.1,76.01,78.2,80.05,81.98,83.95,86.13,89.01,95.06,N,N,singlePerformanceRate
Age Appropriate Screening Colonoscopy,439,MIPS CQM,Efficiency,1.0230577938806282,0.14,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.16,1.19,Y,Y,singlePerformanceRate
Skin Cancer: Biopsy Reporting Time - Pathologist to Clinician,440,MIPS CQM,Process,3.3881460926321445,99.31,Yes,Yes,86.11,98.6,99.69,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,MIPS CQM,Intermediate Outcome,21.231713717202634,53.21,No,No,1.72,28.41,35.0,43.92,49.23,51.82,56.02,61.11,68.17,79.21,100.0,Y,N,singlePerformanceRate
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,MIPS CQM,Process,0.8929042160512458,0.34,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.24,0.94,3.91,Y,Y,singlePerformanceRate
Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer,450,MIPS CQM,Process,10.627812612333027,92.89,Yes,No,42.86,80.43,85.16,90.0,95.45,98.8,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score – better),453,MIPS CQM,Process,7.176918211891407,8.37,No,No,0.0,0.0,0.24,3.61,6.25,7.655,9.52,10.87,14.11,17.95,27.78,Y,Y,singlePerformanceRate
Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better),457,MIPS CQM,Outcome,11.792746564255154,8.66,No,No,0.0,0.0,0.0,0.0,3.45,4.88,6.25,10.26,15.0,24.32,60.0,Y,Y,singlePerformanceRate
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,MIPS CQM,Process,2.947894435704043,98.99,Yes,Yes,85.95,96.48,99.33,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use,464,MIPS CQM,Process,4.788035514516309,97.01,Yes,Yes,82.19,91.61,94.02,97.66,98.25,98.89,99.5,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status After Primary Total Knee Replacement,470,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),24.998874232670975,28.10,No,No,0.15,3.57,6.75,11.54,15.425,19.57,28.78,34.81,44.92,60.66,100.0,Y,N,singlePerformanceRate
Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture,472,eCQM,Process,2.6985987733566548,0.84,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.5,2.7,12.83,Y,Y,singlePerformanceRate
HIV Screening,475,eCQM,Process,19.23410642216876,20.91,No,No,0.1,0.88,2.6,4.795,9.09,16.97,23.69,30.36,37.595,47.715,79.02,N,N,singlePerformanceRate
Multimodal Pain Management,477,MIPS CQM,Process,7.2503482395446115,97.47,Yes,Yes,58.02,94.72,97.62,99.06,99.79,99.95,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Neck Impairments,478,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.587021704774155,79.62,No,No,23.81,47.06,57.14,68.18,77.78,87.235,95.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
"Hospital-Wide, 30-Day, All-Cause Unplanned Readmission (HWR) Rate for the Merit-Based Incentive Payment System (MIPS) Groups",479,Administrative Claims,Outcome,0.013042392782662643,0.1507,No,No,0.1203,0.1343,0.1401,0.1442,0.1474,0.1507,0.1538,0.1574,0.1612,0.1671,0.1828,Y,Y,costScore
Risk-standardized complication rate (RSCR) following elective primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA) for Merit-based Incentive Payment System (MIPS),480,Administrative Claims,Outcome,0.007350920655753544,0.0297,No,No,0.017,0.0221,0.024,0.0253,0.0268,0.0286,0.0301,0.0319,0.0348,0.0388,0.0542,Y,Y,costScore
Clinician and Clinician Group Risk-standardized Hospital Admission Rates for Patients with Multiple Chronic Conditions,484,Administrative Claims,Outcome,10.084231883561067,37.25,No,No,20.4668,27.4856,30.2147,32.1623,33.9919,35.8348,37.701,39.9786,43.0905,47.5848,73.5166,Y,Y,costScore
Psoriasis- Improvement in Patient-Reported Itch Severity,485,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),24.927472244119777,52.11,No,No,4.44,22.58,32.09,38.22,43.1,48.0,53.85,61.67,71.64,96.97,100.0,Y,N,singlePerformanceRate
Dermatitis – Improvement in Patient-Reported Itch Severity,486,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),25.55816465483287,48.20,No,No,6.45,19.23,26.42,32.26,37.83,42.6,49.47,56.32,70.0,95.12,100.0,Y,N,singlePerformanceRate
Screening for Social Drivers of Health,487,MIPS CQM,Process,44.242929940607006,47.36,No,No,0.01,0.05,0.26,3.17,11.95,30.78,76.76,99.19,100.0,100.0,100.0,Y,N,singlePerformanceRate
Kidney Health Evaluation,488,MIPS CQM,Process,26.291451391400408,48.67,No,No,1.91,15.87,24.81,33.51,43.36,47.19,51.045,54.65,66.99,96.25,100.0,N,N,singlePerformanceRate
Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy,489,MIPS CQM,Process,19.21263005422383,87.14,Yes,No,25.0,60.93,70.41,77.81,95.09,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
"Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma",491,MIPS CQM,Process,14.45814118879043,92.70,Yes,No,20.29,75.76,88.75,95.31,97.87,99.675,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Risk-Standardized Acute Cardiovascular-Related Hospital Admission Rates for Patients with Heart Failure under the Merit-based Incentive Payment System,492,Administrative Claims,Outcome,4.061794786278504,67.72,No,No,58.2772,63.0074,64.6577,65.629,66.5205,67.4325,68.3293,69.5003,70.8413,72.7608,78.401,Y,Y,costScore
Adult Immunization Status,493,MIPS CQM,Process,21.272902685994772,19.93,No,No,0.02,0.54,2.06,4.26,7.64,12.68,18.955,27.46,36.15,48.18,100.0,N,N,multiPerformanceRate
Preventive Care and Wellness (composite),497,MIPS CQM,Process,16.233515429510522,25.55,No,No,0.09,5.02,10.63,15.56,19.95,24.07,28.26,32.86,38.86,47.46,69.59,N,N,multiPerformanceRate
Connection to Community Service Provider,498,MIPS CQM,Process,28.620869216474432,13.12,No,No,0.05,0.78,1.52,1.92,2.32,2.56,2.8,3.57,4.81,53.57,100.0,Y,N,singlePerformanceRate
Appropriate screening and plan of care for elevated intraocular pressure following intravitreal or periocular steroid therapy,499,MIPS CQM,Process,21.993334989430288,71.11,No,No,4.39,42.86,53.16,63.89,70.45,76.27,80.65,84.85,89.66,94.94,100.0,N,N,singlePerformanceRate
Acute posterior vitreous detachment appropriate examination and follow-up,500,MIPS CQM,Process,32.65726681530838,66.81,No,No,0.03,23.36,31.18,45.0,55.56,72.81,93.75,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Melanoma: – Appropriate Surgical Margins,AAD12,QCDR Measure,Intermediate Outcome,13.88126792793034,92.15,No,No,38.38,75.27,84.48,93.75,96.7,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Psoriasis – Appropriate Assessment & Treatment of Severe Psoriasis,AAD15,QCDR Measure,Process,25.622223637774773,75.89,No,No,6.45,34.32,54.035,69.57,76.25,86.42,91.67,95.0,97.855,100.0,100.0,N,N,registrySinglePerformanceRate
Avoidance of Post-operative Systemic Antibiotics for Office-based Closures and Reconstruction After Skin Cancer Procedures,AAD16,QCDR Measure,Process,12.429495845646775,4.51,Yes,No,0.0,0.0,0.0,0.0,0.0,0.305,1.69,3.06,5.02,11.76,83.33,Y,Y,registryMultiPerformanceRate
Continuation of Anticoagulation Therapy in the Office-based Setting for Closure and Reconstruction After Skin Cancer Resection Procedures,AAD17,QCDR Measure,Process,0.4723619443304176,99.92,Yes,No,97.37,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registryMultiPerformanceRate
Avoidance of Opioid Prescriptions for Closure and Reconstruction After Skin Cancer Resection,AAD18,QCDR Measure,Process,1.0952402432691153,0.15,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,8.27,Y,Y,registryMultiPerformanceRate
Psoriasis – Shared Decision Making in the Treatment of Psoriasis,AAD19,QCDR Measure,Process,26.36136467253315,85.23,Yes,No,0.22,44.21,81.11,89.66,94.51,98.13,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Skin Cancer: Biopsy Reporting Time - Clinician to Patient,AAD6,QCDR Measure,Process,11.691820601868857,96.32,Yes,Yes,29.12,90.56,96.815,98.905,99.475,99.8,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Psoriasis: Screening for Psoriatic Arthritis,AAD7,QCDR Measure,Process,14.679213663187083,92.25,Yes,Yes,28.21,76.69,91.27,95.12,96.8,98.23,98.78,99.53,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Chronic Skin Conditions: Patient Reported Quality-of-Life,AAD8,QCDR Measure,Process,33.57856002471418,36.45,No,No,0.76,3.78,5.43,11.48,15.86,21.4,28.17,58.97,74.94,83.46,95.57,Y,N,registrySinglePerformanceRate
Age-Related Hearing Loss: Comprehensive Audiometric Evaluation,AAO16,QCDR Measure,Process,18.759416475210106,80.41,No,No,6.25,51.92,66.075,71.31,80.7,85.19,91.2,94.47,96.325,98.82,100.0,Y,N,registrySinglePerformanceRate
Tympanostomy Tubes: Comprehensive Audiometric Evaluation,AAO20,QCDR Measure,Process,32.08112737181247,67.61,No,No,3.65,19.33,25.64,41.96,68.89,81.565,93.07,95.05,95.58,97.07,100.0,N,N,registrySinglePerformanceRate
Otitis Media with Effusion (OME): Comprehensive Audiometric Evaluation for Chronic OME > or = 3 months,AAO21,QCDR Measure,Process,28.475825343244733,70.03,No,No,3.16,28.57,44.44,56.78,63.33,79.31,87.22,93.18,97.37,100.0,100.0,N,N,registrySinglePerformanceRate
Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines,AAO23,QCDR Measure,Process,22.821462604623836,73.34,No,No,13.75,42.13,52.4,59.24,70.1,76.6,84.96,91.01,96.32,99.77,100.0,N,N,registrySinglePerformanceRate
Standard Benign Positional Paroxysmal Vertigo (BPPV) Management,AAO32,QCDR Measure,Process,0.0,0.00,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,Y,Y,registrySinglePerformanceRate
Tympanostomy Tubes: Resolution of Otitis Media with Effusion (OME) in Adults and Children,AAO36,QCDR Measure,Outcome,30.246313829703286,23.71,No,No,0.56,1.08,2.33,3.23,3.64,8.62,15.31,19.62,52.71,82.86,89.66,Y,N,registrySinglePerformanceRate
Dysphonia: Laryngeal Examination,AAO37,QCDR Measure,Process,22.805914060702417,74.31,No,No,3.67,42.31,58.895,66.94,72.075,80.77,88.56,90.0,92.59,95.42,100.0,Y,N,registrySinglePerformanceRate
Neck Mass Evaluation,AAO39,QCDR Measure,Process,8.683601852777805,10.83,No,No,1.37,1.6,2.27,3.77,9.09,10.64,11.61,14.75,16.9,21.43,39.13,Y,N,registrySinglePerformanceRate
Measuring the Value-Functions of Primary Care: Physician Level Continuity of Care Measure,ABFM12,QCDR Measure,Efficiency,23.292764537533852,81.79,No,No,25.25,46.07,56.05,68.2,85.085,96.37,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Low Flow Inhalational General Anesthesia,ABG44,QCDR Measure,Efficiency,11.09032472081532,95.52,No,No,32.19,86.87,96.0,98.58,99.24,99.34,99.6,99.82,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,QCDR Measure,Process,17.332456359859226,69.53,No,No,27.91,48.87,55.27,60.08,63.54,66.45,74.41,79.9,82.71,97.9,100.0,Y,N,registrySinglePerformanceRate
Tobacco Use: Screening and Cessation Intervention for Patients with Asthma and COPD,ACEP25,QCDR Measure,Process,14.208665653869875,88.06,No,No,21.62,76.64,80.945,86.75,89.58,92.53,94.495,96.81,97.975,98.88,99.48,N,N,registrySinglePerformanceRate
Sepsis Management: Septic Shock: Lactate Clearance Rate of >=10%,ACEP30,QCDR Measure,Outcome,8.533100223265274,75.45,No,No,57.69,62.9,69.33,70.68,73.17,76.4,78.87,80.3,81.4,86.11,95.24,Y,N,registrySinglePerformanceRate
Appropriate Foley catheter use in the emergency department,ACEP31,QCDR Measure,Process,22.937390463624848,85.76,Yes,No,20.42,42.76,59.22,91.18,95.89,98.27,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
"Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,QCDR Measure,Process,11.409715431672385,88.15,No,No,26.7,77.84,83.55,87.8,88.79,90.35,92.13,93.48,94.77,97.5,100.0,N,N,registrySinglePerformanceRate
ED Median Time from ED arrival to ED departure for all Adult Patients,ACEP50,QCDR Measure,Outcome,41.4540148774804,177.21,No,No,98.0,132.0,147.0,155.0,161.0,171.0,180.0,193.0,208.0,226.0,301.0,Y,Y,nonProportion
ED Median Time from ED arrival to ED departure for all Pediatric ED Patients,ACEP51,QCDR Measure,Outcome,27.512929693320515,121.03,No,No,68.0,90.0,99.0,105.0,113.0,119.0,125.0,133.0,140.0,164.0,184.0,Y,Y,nonProportion
Appropriate Use of Imaging for Recurrent Renal Colic,ACEP53,QCDR Measure,Process,20.93356964052564,54.99,No,No,27.96,32.275,36.24,42.155,45.345,46.515,55.61,65.725,75.255,86.83,100.0,Y,N,registrySinglePerformanceRate
Chest Pain – Avoidance of admission for adult patients with low-risk chest pain.,ACEP59,QCDR Measure,Outcome,6.670098625901303,93.38,No,No,64.15,85.24,88.19,90.79,93.07,95.62,97.23,98.05,98.79,99.82,100.0,Y,N,registrySinglePerformanceRate
Syncope – Avoidance of admission for adult patients with low-risk syncope,ACEP60,QCDR Measure,Outcome,5.6906187411562845,90.84,No,No,71.89,83.67,86.3,88.35,90.36,91.57,92.84,93.94,95.78,97.99,100.0,Y,N,registrySinglePerformanceRate
"Avoidance of Chest X-ray in pediatric patients with Asthma, Bronchiolitis or Croup",ACEP61,QCDR Measure,Process,13.043124766297009,33.89,No,No,0.91,19.87,24.75,27.72,30.77,33.875,37.78,40.3,43.35,51.5,63.16,Y,Y,registrySinglePerformanceRate
Avoidance of Opioid therapy for dental pain.,ACEP62,QCDR Measure,Process,7.9562218883019336,85.13,No,No,65.79,75.93,80.29,81.72,83.17,85.045,87.5,88.89,92.02,96.09,99.39,Y,N,registrySinglePerformanceRate
Avoidance of Acute High-Risk Prescriptions in geriatric patients at discharge,ACEP63,QCDR Measure,Process,2.0870406658622613,4.68,Yes,No,0.03,1.89,3.25,3.75,4.24,4.68,5.2,5.52,6.22,6.68,11.59,Y,Y,registrySinglePerformanceRate
Avoidance of admission for adult patients in Emergency Department with low-risk Deep Vein Thrombosis (DVT).,ACEP64,QCDR Measure,Outcome,21.461711470545072,72.28,No,No,27.11,44.44,52.03,57.56,63.72,69.74,79.72,91.89,97.37,100.0,100.0,Y,N,registrySinglePerformanceRate
Appropriate Utilization of Imaging in rAAA (ruptured Abdominal Aortic Aneurysm) patients in Emergency Department,ACEP65,QCDR Measure,Process,26.443496718176483,57.78,No,No,1.68,13.395,33.065,48.855,60.6,62.5,69.805,78.98,82.38,84.31,86.11,Y,N,registrySinglePerformanceRate
"Co-testing for HIV in high-risk patients in Emergency Department who are being tested for other sexually transmitted infections (STI) (Gonorrhea, Chlamydia, Syphilis or Trichomonas).",ACEP66,QCDR Measure,Process,9.280011447688032,11.33,No,No,0.18,1.47,2.54,4.42,6.77,9.61,12.02,15.25,20.3,23.91,41.05,N,N,registrySinglePerformanceRate
Hepatitis B Safety Screening,ACR10,QCDR Measure,Process,20.21376503917129,62.13,No,No,9.74,33.82,43.88,52.62,58.41,65.64,68.85,71.91,83.08,86.84,98.0,Y,N,registrySinglePerformanceRate
Disease Activity Measurement for Patients with PsA,ACR12,QCDR Measure,Process,18.493100354792443,87.44,No,No,11.79,67.27,83.02,86.52,90.91,93.81,96.15,97.48,99.18,100.0,100.0,N,N,registrySinglePerformanceRate
Gout: Serum Urate Target,ACR14,QCDR Measure,Intermediate Outcome,16.626304134748214,61.98,No,No,10.59,41.18,50.0,55.0,59.77,62.65,65.9,69.93,75.51,81.16,100.0,Y,N,registrySinglePerformanceRate
Safe Hydroxychloroquine Dosing,ACR15,QCDR Measure,Process,15.082424621657555,75.01,No,No,31.57,56.52,62.95,69.55,71.99,76.36,80.07,85.0,88.68,91.98,99.55,Y,N,registrySinglePerformanceRate
Rheumatoid Arthritis Patients with Low Disease Activity or Remission,ACR16,QCDR Measure,Intermediate Outcome,1.35046664299647,99.62,Yes,No,94.83,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Report Turnaround Time: Radiography,ACRAD15,QCDR Measure,Outcome,13.572640061764679,6.31,No,No,0.2349,0.57,0.86,1.22,1.81,2.2883,2.95,3.8,5.37,14.39,92.32,Y,Y,nonProportion
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,QCDR Measure,Outcome,12.057005177554487,6.30,No,No,0.32,0.59,0.96,1.3386,2.04,2.74,3.35,4.43,8.05,15.05,67.11,Y,Y,nonProportion
Report Turnaround Time: MRI,ACRAD17,QCDR Measure,Outcome,13.019274325161431,12.19,No,No,0.78,2.17,3.37,5.039,6.045,7.81,10.64,13.29,16.01,27.35,65.4,Y,Y,nonProportion
Report Turnaround Time: CT,ACRAD18,QCDR Measure,Outcome,18.94295151538001,7.34,No,No,0.46,0.82,1.25,1.93,2.45,2.94,3.79,4.68,7.02,14.4,48.22,Y,Y,nonProportion
Report Turnaround Time: PET,ACRAD19,QCDR Measure,Outcome,10.226178882972183,9.67,No,No,0.2068,1.93,2.5101,3.11,3.985,6.79,8.565,10.79,15.01,18.28,48.16,Y,Y,nonProportion
Report Turnaround Time: Mammography,ACRAD25,QCDR Measure,Outcome,25.38582911684385,19.41,No,No,0.33,1.1,3.18,5.59,7.12,9.215,12.9,20.53,31.69,50.23,135.38,Y,Y,nonProportion
"Multi-strata weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan)",ACRAD34,QCDR Measure,Outcome,12.215385111602698,86.30,No,No,37.32,70.38,81.7,82.07,86.9,89.71,91.23,94.32,96.0,96.61,99.93,Y,N,registryMultiPerformanceRate
Incidental Coronary Artery Calcification Reported on Chest CT,ACRAD36,QCDR Measure,Process,18.36618573235509,92.35,Yes,No,18.77,65.99,93.3,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Interpretation of CT Pulmonary Angiography (CTPA) for Pulmonary Embolism,ACRAD37,QCDR Measure,Process,2.5199889442371526,99.37,Yes,No,85.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Use of Quantitative Criteria for Oncologic FDG PET Imaging,ACRAD41,QCDR Measure,Process,25.657347252704103,90.97,Yes,No,0.15,64.92,99.42,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Patient-Reported Experience with Anesthesia,AQI48,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),3.159883219633676,94.73,No,No,83.33,89.72,92.84,94.2,94.75,95.68,95.97,96.47,97.14,97.78,98.75,Y,N,registryMultiPerformanceRate
Avoidance of Cerebral Hyperthermia for Procedures Involving Cardiopulmonary Bypass,AQI65,QCDR Measure,Outcome,13.444159992157816,93.52,No,No,48.08,75.875,88.355,96.91,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Perioperative Anemia Management,AQI72,QCDR Measure,Process,2.9666570664971785,99.17,Yes,Yes,85.71,98.67,99.46,99.81,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment,AQUA14,QCDR Measure,Outcome,4.72661797274938,4.20,No,No,0.0,0.0,0.62,1.52,2.33,2.685,3.45,4.5,8.27,10.28,21.54,Y,Y,registrySinglePerformanceRate
Stones: Urinalysis or Urine Culture Performed Before Surgical Stone Procedures,AQUA15,QCDR Measure,Process,17.261867699679264,86.83,No,No,31.71,53.73,80.19,87.27,90.91,94.74,96.3,97.2,98.14,100.0,100.0,Y,N,registrySinglePerformanceRate
Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH,AQUA26,QCDR Measure,Process,11.799544148197555,3.11,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.35,2.63,6.43,86.8,Y,Y,registrySinglePerformanceRate
Hospital admissions or infectious complications within 30 days of prostate biopsy,AQUA8,QCDR Measure,Outcome,3.0973599997827126,2.08,No,No,0.0,0.0,0.0,0.0,0.63,0.98,1.32,2.2,3.41,6.23,14.52,Y,Y,registrySinglePerformanceRate
Biopsy Reporting Time to Clinician,CAP22,QCDR Measure,Process,12.975743429991809,93.53,Yes,No,44.03,91.93,94.17,95.8,96.73,97.53,98.76,99.12,99.59,100.0,100.0,Y,N,registrySinglePerformanceRate
Gastritis: Timely Helicobacter pylori Reporting,CAP28,QCDR Measure,Process,9.320938700307577,94.21,Yes,Yes,50.01,86.95,90.88,94.33,96.62,97.625,98.67,99.28,99.74,100.0,100.0,Y,N,registrySinglePerformanceRate
Urinary Bladder Cancer: Complete Analysis and Timely Reporting,CAP30,QCDR Measure,Process,12.657724388180839,91.12,Yes,No,32.56,72.32,80.09,92.11,95.12,95.81,98.31,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Prostate Cancer Reporting: Complete Analysis,CAP38,QCDR Measure,Process,10.349501924734836,97.54,Yes,No,18.25,96.54,99.7,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Squamous Cell Skin Cancer: Complete Reporting,CAP40,QCDR Measure,Process,29.600093804341334,83.77,Yes,No,0.1,35.71,70.91,94.52,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Basal Cell Skin Cancer: Complete Reporting,CAP41,QCDR Measure,Process,20.46951665938665,90.95,Yes,No,0.06,76.04,83.83,95.96,99.39,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Asthma/Chronic Obstructive Pulmonary Disease (COPD),COST_ACOPD_1,Administrative Claims,Cost,1357.2767097077044,4837.97,No,No,0.0,2686.27,3364.89,4043.52,5400.77,6079.4,6758.02,7436.65,7775.96,8115.27,8454.59,,Y,costScore
Acute Kidney Injury Requiring New Inpatient Dialysis,COST_AKID_1,Administrative Claims,Cost,10424.571968311866,50121.07,No,No,0.0,32600.37,37811.34,43022.32,53444.28,58655.26,63866.23,69077.21,71682.7,74288.19,76893.68,,Y,costScore
Revascularization for Lower Extremity Chronic Critical Limb Ischemia,COST_CCLI_1,Administrative Claims,Cost,4276.787210573709,23330.20,No,No,0.0,16444.65,18582.7,20720.75,24996.85,27134.9,29272.95,31410.99,32480.02,33549.04,34618.07,,Y,costScore
Inpatient Chronic Obstructive Pulmonary Disease (COPD) Exacerbation,COST_COPDE_1,Administrative Claims,Cost,2339.1040729429337,16405.12,No,No,0.0,12567.11,13736.32,14905.54,17243.96,18413.18,19582.39,20751.6,21336.21,21920.82,22505.42,,Y,costScore
Colon and Rectal Resection,COST_CRR_1,Administrative Claims,Cost,1917.5870168635279,27657.71,No,No,0.0,24624.16,25582.3,26540.45,28456.75,29414.9,30373.04,31331.19,31810.27,32289.34,32768.41,,Y,costScore
Depression,COST_DEP_1,Administrative Claims,Cost,713.1231157416692,1783.58,No,No,0.0,573.84,930.39,1286.94,2000.05,2356.6,2713.15,3069.71,3247.98,3426.26,3604.54,,Y,costScore
Diabetes,COST_D_1,Administrative Claims,Cost,1862.913374589129,7370.49,No,No,0.0,4376.43,5307.87,6239.32,8102.22,9033.67,9965.11,10896.56,11362.29,11828.01,12293.73,,Y,costScore
Emergency Medicine,COST_EDV_1,Administrative Claims,Cost,786.156367226751,6332.30,No,No,0.0,5072.92,5465.98,5859.03,6645.13,7038.18,7431.24,7824.29,8020.81,8217.34,8413.87,,Y,costScore
Elective Outpatient Percutaneous Coronary Intervention (PCI),COST_EOPCI_1,Administrative Claims,Cost,1432.23216625779,11719.69,No,No,0.0,9701.63,10417.66,11133.68,12565.72,13281.74,13997.77,14713.79,15071.8,15429.81,15787.82,,Y,costScore
Femoral or Inguinal Hernia Repair,COST_FIHR_1,Administrative Claims,Cost,600.595332640386,5698.34,No,No,0.0,4945.74,5245.98,5546.22,6146.7,6446.94,6747.18,7047.42,7197.54,7347.65,7497.77,,Y,costScore
Hemodialysis Access Creation,COST_HAC_1,Administrative Claims,Cost,1267.4119261253597,6673.61,No,No,0.0,4681.9,5315.36,5948.82,7215.74,7849.2,8482.66,9116.12,9432.85,9749.58,10066.31,,Y,costScore
Heart Failure,COST_HF_1,Administrative Claims,Cost,3757.337255733955,14029.22,No,No,0.0,8003.31,9881.94,11760.57,15517.83,17396.46,19275.09,21153.72,22093.03,23032.35,23971.66,,Y,costScore
Intracranial Hemorrhage or Cerebral Infarction,COST_IHCI_1,Administrative Claims,Cost,5060.370345459908,28546.95,No,No,0.0,20383.69,22913.06,25442.43,30501.17,33030.54,35559.91,38089.28,39353.97,40618.65,41883.34,,Y,costScore
Routine Cataract Removal with Intraocular Lens (IOL) Implantation,COST_IOL_1,Administrative Claims,Cost,302.7710192078478,3297.49,No,No,0.0,2789.45,2940.82,3092.2,3394.96,3546.34,3697.71,3849.09,3924.78,4000.47,4076.16,,Y,costScore
Knee Arthroplasty,COST_KA_1,Administrative Claims,Cost,1813.4601340941329,16920.64,No,No,0.0,14234.28,15140.96,16047.63,17860.97,18767.64,19674.32,20580.99,21034.33,21487.66,21941.0,,Y,costScore
Low Back Pain,COST_LBP_1,Administrative Claims,Cost,571.1664507186292,1946.90,No,No,0.0,1011.59,1297.16,1582.74,2153.9,2439.48,2725.05,3010.63,3153.42,3296.21,3439.0,,Y,costScore
Lower Gastrointestinal Hemorrhage (groups only),COST_LGH_1,Administrative Claims,Cost,1053.529439195115,13237.58,No,No,0.0,11586.17,12112.61,12639.06,13691.94,14218.39,14744.83,15271.28,15534.5,15797.72,16060.95,,Y,costScore
"Lumpectomy, Partial Mastectomy, Simple Mastectomy",COST_LPMSM_1,Administrative Claims,Cost,845.1507142717264,6833.03,No,No,0.0,5594.25,6016.67,6439.1,7283.95,7706.38,8128.8,8551.23,8762.44,8973.65,9184.86,,Y,costScore
"Lumbar Spine Fusion for Degenerative Disease, 1-3 Levels",COST_LSFDD_1,Administrative Claims,Cost,3679.2621373080096,40975.90,No,No,0.0,35006.94,36846.23,38685.51,42364.09,44203.37,46042.66,47881.94,48801.59,49721.23,50640.87,,Y,costScore
Melanoma Resection,COST_MR_1,Administrative Claims,Cost,378.50712339840754,1626.84,No,No,0.0,1011.07,1200.3,1389.53,1767.99,1957.22,2146.45,2335.68,2430.3,2524.91,2619.53,,Y,costScore
Non-Emergent Coronary Artery Bypass Graft (CABG),COST_NECABG_1,Administrative Claims,Cost,3961.218352584365,48771.77,No,No,0.0,42293.04,44272.47,46251.91,50210.79,52190.23,54169.66,56149.1,57138.82,58128.54,59118.26,,Y,costScore
Elective Primary Hip Arthroplasty,COST_PHA_1,Administrative Claims,Cost,2232.284127070628,17808.52,No,No,0.0,14310.78,15426.82,16542.86,18774.94,19890.98,21007.02,22123.06,22681.08,23239.1,23797.12,,Y,costScore
Psychoses and Related Conditions,COST_PRC_1,Administrative Claims,Cost,4758.157925043488,21597.62,No,No,0.0,13974.27,16352.35,18730.42,23486.58,25864.65,28242.73,30620.81,31809.85,32998.89,34187.93,,Y,costScore
Renal or Ureteral Stone Surgical Treatment,COST_RUSST_1,Administrative Claims,Cost,901.1697141914769,6874.32,No,No,0.0,5439.53,5890.07,6340.6,7241.68,7692.21,8142.75,8593.29,8818.55,9043.82,9269.09,,Y,costScore
Screening/Surveillance Colonoscopy,COST_SSC_1,Administrative Claims,Cost,144.80813519263634,1152.47,No,No,0.0,936.07,1008.47,1080.87,1225.67,1298.07,1370.47,1442.87,1479.07,1515.27,1551.47,,Y,costScore
ST-Elevation Myocardial Infarction (STEMI) with Percutaneous Coronary Intervention (PCI),COST_STEMI_1,Administrative Claims,Cost,1855.3270969656169,22340.67,No,No,0.0,19264.58,20190.54,21116.49,22968.41,23894.36,24820.32,25746.28,26209.26,26672.23,27135.21,,Y,costScore
Sepsis,COST_S_1,Administrative Claims,Cost,3481.197499904293,26163.34,No,No,0.0,20737.99,22478.5,24219.0,27700.0,29440.5,31181.01,32921.51,33791.76,34662.01,35532.26,,Y,costScore
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,QCDR Measure,Process,6.783542013839168,96.37,Yes,Yes,62.58,91.64,94.74,96.74,97.92,98.885,99.82,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Avoidance of Opiates for Low Back Pain or Migraines,ECPR46,QCDR Measure,Process,3.6336093215840877,96.90,Yes,Yes,86.7,91.31,94.08,95.78,97.32,98.095,98.66,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions and Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain,ECPR55,QCDR Measure,Process,7.543606485907733,90.82,No,No,77.06,80.5,83.03,85.26,88.59,91.83,93.94,97.16,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Functional Status Change in Balance Confidence,FOTO5,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),23.484402246249243,62.72,No,No,6.25,33.82,42.86,45.45,52.38,61.11,76.32,80.0,81.48,93.33,100.0,Y,N,registrySinglePerformanceRate
Functional Status Change in Dizziness,FOTO6,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),17.190619661121392,79.90,No,No,38.75,53.24,64.405,75.0,79.585,85.37,90.835,91.67,92.585,97.56,100.0,Y,N,registrySinglePerformanceRate
Appropriate follow-up interval based on pathology findings in screening colonoscopy,GIQIC23,QCDR Measure,Process,22.161691355113177,87.02,Yes,No,8.0,43.94,83.4,91.84,93.39,95.515,98.1,99.16,100.0,100.0,100.0,Y,N,registryMultiPerformanceRate
Screening Colonoscopy Adenoma Detection Rate,GIQIC26,QCDR Measure,Outcome,9.060305465412428,40.19,No,No,19.91,27.425,31.76,36.11,38.085,39.61,42.66,45.11,47.535,52.05,60.8,Y,N,registryMultiPerformanceRate
Appropriate Utilization of Vancomycin for Cellulitis,HCPR24,QCDR Measure,Process,13.736011217477463,88.70,No,No,47.79,73.72,76.24,82.13,86.8,94.93,98.7,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,QCDR Measure,Outcome,0.6545920910472524,99.70,Yes,No,96.97,99.04,99.43,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Glaucoma – Intraocular Pressure Reduction,IRIS2,QCDR Measure,Intermediate Outcome,4.639099989557029,92.40,No,No,77.78,87.01,89.5,90.83,91.93,92.98,93.98,94.91,96.04,97.47,100.0,Y,N,registrySinglePerformanceRate
Refractive Surgery: Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better within 30 days,IRIS23,QCDR Measure,Outcome,12.82254047627592,87.77,No,No,14.81,75.86,81.48,84.61,88.71,90.58,93.33,94.64,96.67,98.3,100.0,Y,N,registrySinglePerformanceRate
Intraocular Pressure Reduction Following Trabeculectomy or an Aqueous Shunt Procedure,IRIS39,QCDR Measure,Outcome,21.77120424216001,49.45,No,No,17.78,26.11,31.82,34.92,40.0,44.325,54.9,59.37,60.46,85.29,100.0,Y,N,registrySinglePerformanceRate
Complications After Cataract Surgery,IRIS54,QCDR Measure,Outcome,0.9821940682744031,0.45,No,No,0.0,0.0,0.0,0.0,0.0,0.19,0.325,0.49,0.705,1.13,3.32,Y,Y,registrySinglePerformanceRate
Improved Visual Acuity after Vitrectomy for Complications of Diabetic Retinopathy within 120 Days,IRIS58,QCDR Measure,Outcome,5.641464986552008,86.38,No,No,70.0,80.77,81.82,83.78,84.61,85.71,87.04,89.65,91.04,94.54,100.0,Y,N,registrySinglePerformanceRate
Visual Acuity Improvement Following Cataract Surgery and Minimally Invasive Glaucoma Surgery,IRIS61,QCDR Measure,Outcome,16.235567334147593,82.99,No,No,26.32,61.22,70.73,80.64,85.0,88.28,90.91,93.1,95.77,97.67,100.0,Y,N,registrySinglePerformanceRate
Regaining Vision After Cataract Surgery,IRIS62,QCDR Measure,Outcome,13.690733995540045,79.04,No,No,28.57,61.82,70.0,75.0,78.26,80.56,84.09,86.96,90.48,94.2,100.0,Y,N,registrySinglePerformanceRate
Use of Anxiety Severity Measure,MBHR1,QCDR Measure,Process,16.280324496590527,92.39,Yes,No,25.2,86.11,89.19,93.24,95.87,98.28,99.23,100.0,100.0,100.0,100.0,N,N,registrySinglePerformanceRate
Hammer Toe Outcome,MEX5,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),27.64469153818769,26.49,No,No,0.89,2.13,4.72,6.3,12.43,15.59,20.75,32.0,50.0,74.01,100.0,Y,N,registrySinglePerformanceRate
Patients Suffering From a Neck Injury who Improve Physical Function,MSK1,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),13.363194887427525,56.49,No,No,33.33,41.67,45.83,50.0,53.06,55.17,58.06,60.71,63.16,69.23,95.51,Y,N,registrySinglePerformanceRate
Patients Suffering From a Knee Injury who Improve Pain,MSK10,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),5.95702128637333,53.82,No,No,40.0,46.67,48.57,50.0,52.17,53.85,55.56,57.14,59.09,61.29,66.67,Y,N,registrySinglePerformanceRate
Patients Suffering From an Upper Extremity Injury who Improve Physical Function,MSK2,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),10.12819825111642,54.51,No,No,38.71,45.37,48.37,50.0,52.05,53.37,54.72,56.25,58.12,60.71,96.79,Y,N,registrySinglePerformanceRate
Patients Suffering From a Back Injury who Improve Physical Function,MSK3,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),10.994497349126016,53.42,No,No,33.33,41.67,45.16,48.15,50.0,53.29,55.22,56.86,58.82,61.9,93.24,Y,N,registrySinglePerformanceRate
Patients Suffering From a Lower Extremity Injury who Improve Physical Function,MSK4,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),7.599697628384073,55.42,No,No,36.67,45.71,49.89,51.79,53.85,55.56,57.14,59.63,62.09,65.0,70.73,Y,N,registrySinglePerformanceRate
Patients Suffering From a Knee Injury who Improve Physical Function,MSK5,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),5.990619292747465,53.12,No,No,36.0,46.43,49.28,50.94,52.17,53.47,54.81,56.0,57.14,58.97,69.23,Y,N,registrySinglePerformanceRate
Patients Suffering From a Neck Injury who Improve Pain,MSK6,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),8.34891707430876,53.80,No,No,33.33,42.86,46.67,50.0,52.26,54.17,56.25,59.09,60.87,63.64,71.43,Y,N,registrySinglePerformanceRate
Patients Suffering From an Upper Extremity Injury who Improve Pain,MSK7,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),6.576334362703103,53.50,No,No,37.5,45.0,48.28,50.0,52.11,53.57,55.32,57.18,59.26,61.9,66.67,Y,N,registrySinglePerformanceRate
Patients Suffering From a Back Injury who Improve Pain,MSK8,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),7.753100222525975,54.48,No,No,37.14,44.0,47.62,50.0,52.74,55.0,57.14,59.09,61.22,64.29,70.0,Y,N,registrySinglePerformanceRate
Patients Suffering From a Lower Extremity Injury who Improve Pain,MSK9,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),7.051190931033898,55.13,No,No,40.0,46.67,50.0,51.32,53.33,54.89,56.61,58.85,61.54,64.29,69.88,Y,N,registrySinglePerformanceRate
Screening Coronary Calcium Scoring for Cardiovascular Risk Assessment Including Coronary Artery Calcification Regional Distribution Scoring,MSN13,QCDR Measure,Process,27.92085614382199,87.36,Yes,No,0.65,52.27,82.16,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,registrySinglePerformanceRate
Use of Thyroid Imaging Reporting & Data System (TI-RADS) in Final Report to Stratify Thyroid Nodule Risk,MSN15,QCDR Measure,Process,13.130815169955769,96.01,Yes,Yes,10.67,88.64,98.235,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Medicare Spending Per Beneficiary (MSPB) Clinician,MSPB_1,Administrative Claims,Cost,2411.150176545982,24661.85,No,No,0.0,20870.32,22075.88,23281.44,25692.56,26898.12,28103.68,29309.24,29912.02,30514.8,31117.58,,Y,costScore
Prostate Cancer: Active Surveillance/Watchful Waiting for Newly Diagnosed Low Risk Prostate Cancer Patients,MUSIC4,QCDR Measure,Process,11.185514645814823,76.66,No,No,55.0,61.54,64.71,69.16,76.36,79.28,80.95,81.08,85.71,91.67,100.0,Y,N,registrySinglePerformanceRate
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,QCDR Measure,Process,16.20129447016087,89.71,Yes,No,29.79,61.9,84.38,92.49,95.0,96.265,97.73,99.28,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Oncology: Advance Care Planning in Metastatic Cancer Patients,PIMSH1,QCDR Measure,Patient Engagement/Experience,25.47371814054909,53.16,No,No,0.9,9.2,33.3,44.6,49.0,55.5,60.3,67.8,77.3,87.7,94.4,Y,N,registrySinglePerformanceRate
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs,PIMSH10,QCDR Measure,Process,27.048828886740072,62.24,No,No,1.9,16.0,43.1,54.8,61.5,68.3,71.7,74.6,86.4,93.5,100.0,Y,N,registrySinglePerformanceRate
Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse (Lower Score - Better),PIMSH15,QCDR Measure,Process,13.840122720811728,31.81,No,No,4.9,12.1,20.0,23.8,26.6,31.3,34.7,38.4,46.7,51.7,63.3,Y,Y,registrySinglePerformanceRate
Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center,PIMSH16,QCDR Measure,Process,11.618894839668576,84.22,No,No,57.6,66.7,73.9,78.6,82.4,86.4,90.3,93.2,95.8,97.3,100.0,N,N,registrySinglePerformanceRate
Oncology: Utilization of GCSF in Metastatic Colorectal Cancer,PIMSH2,QCDR Measure,Efficiency,12.40339596034918,18.53,No,No,0.0,3.7,5.4,9.1,14.3,17.4,21.7,24.64,30.0,32.4,48.8,Y,Y,registrySinglePerformanceRate
Oncology: Patient-Reported Pain Improvement,PIMSH4,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),14.067039663048147,57.01,No,No,27.4,36.6,44.5,50.8,54.3,56.8,61.3,64.1,69.45,73.7,85.0,Y,N,registrySinglePerformanceRate
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life,PIMSH9,QCDR Measure,Efficiency,4.373276283811195,5.37,No,No,0.0,0.0,1.4,3.6,3.7,4.7,5.0,6.0,8.3,12.7,18.5,Y,Y,registrySinglePerformanceRate
IVC Filter Management Confirmation,QMM16,QCDR Measure,Process,27.948494345006893,86.12,Yes,No,0.12,26.56,70.9,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Appropriate Follow-up Recommendations for Ovarian-Adnexal Lesions using the Ovarian-Adnexal Reporting and Data System (O-RADS),QMM17,QCDR Measure,Process,44.41254835786103,55.13,No,No,0.06,0.61,1.99,5.56,17.78,76.215,93.19,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Use of Breast Cancer Risk Score on Mammography,QMM18,QCDR Measure,Process,28.09501368417514,87.21,Yes,No,0.03,36.68,86.3,97.71,99.9,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
DEXA/DXA and Fracture Risk Assessment for Patients with Osteopenia,QMM19,QCDR Measure,Process,24.980248892070847,89.67,Yes,No,0.59,64.66,92.87,99.38,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,registrySinglePerformanceRate
Low dose cancer screening recommendation for computed tomography (CT) and computed tomography angiography (CTA) of chest with diagnosis of Emphysema.,QMM23,QCDR Measure,Process,36.03312059435654,77.96,Yes,No,0.65,5.94,40.44,83.78,97.78,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Acute Rib Fracture Numbering on ED Trauma Patients,QMM24,QCDR Measure,Process,12.32424320513923,93.50,Yes,No,35.74,72.58,89.19,97.12,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Screening Abdominal Aortic Aneurysm Reporting with Recommendations,QMM26,QCDR Measure,Process,38.359504354371026,71.69,Yes,No,1.11,6.25,21.27,49.01,90.33,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Appropriate Classification and Follow-up Imaging for Incidental Pancreatic Cysts,QMM27,QCDR Measure,Process,35.41235675550041,76.23,Yes,No,8.7,13.79,28.24,69.29,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Reporting Breast Arterial Calcification (BAC) on Screening Mammography,QMM28,QCDR Measure,Process,46.36378909748526,43.89,No,No,0.01,0.07,0.31,0.67,2.81,7.885,84.41,93.61,99.98,100.0,100.0,N,N,registrySinglePerformanceRate
Tunneled Hemodialysis Catheter Clinical Success Rate,RCOIR12,QCDR Measure,Outcome,7.706761687352553,87.11,Yes,No,69.14,73.48,82.78,85.99,88.27,89.85,90.04,91.75,93.19,93.73,98.74,Y,N,registrySinglePerformanceRate
Heel Pain Treatment Outcomes for Adults,REGCLR1,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),25.913429529878904,44.91,No,No,1.09,13.39,21.03,28.81,34.045,41.82,51.715,57.14,67.63,82.81,100.0,Y,N,registrySinglePerformanceRate
Bunion Outcome - Adult and Adolescent,REGCLR3,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),26.421355022049898,24.83,No,No,1.71,2.65,4.12,6.82,9.09,11.69,25.0,31.48,39.58,72.78,100.0,Y,N,registrySinglePerformanceRate
Arteriovenous Graft Thrombectomy Clinical Success Rate,RPAQIR14,QCDR Measure,Outcome,5.36279716636576,89.45,No,No,75.41,82.86,87.08,87.5,88.89,90.1,90.97,92.54,94.32,95.24,97.87,Y,N,registrySinglePerformanceRate
Arteriovenous Fistulae Thrombectomy Clinical Success Rate,RPAQIR15,QCDR Measure,Outcome,7.492519747982854,88.90,Yes,No,72.73,77.14,81.25,86.49,89.17,90.2,92.0,93.75,96.43,96.55,97.3,Y,N,registrySinglePerformanceRate
Total Per Capita Cost (TPCC),TPCC_1,Administrative Claims,Cost,314.4926618767247,1556.84,No,No,0.0,1046.76,1204.01,1361.25,1675.75,1832.99,1990.24,2147.48,2226.1,2304.73,2383.35,,Y,costScore
Vitamin D level: Effective Control of Low Bone Mass/Osteopenia and Osteoporosis: Therapeutic Level Of 25 OH Vitamin D Level Achieved,UREQA8,QCDR Measure,Outcome,24.46200916646704,62.23,No,No,7.12,18.23,44.15,54.59,62.28,65.53,71.21,80.07,86.91,89.06,93.14,Y,N,registrySinglePerformanceRate
Screening for Osteoporosis for Men Aged 70 Years and Older,UREQA9,QCDR Measure,Process,16.507263382154417,34.69,No,No,9.64,13.84,18.99,22.47,32.19,35.44,37.305,42.97,46.955,52.335,84.0,N,N,registrySinglePerformanceRate
